Precise Insights
Advanced Data and AI for Prostate Cancer
On-demand access to the largest and most sophisticated oncology data for accelerated RWE and improved patient outcomes.
labs
Results from variety of patient tests
Visits
Oncology practice visits
Observations
Tumor-related observations plus vitals, biometrics, pain, and more
Procedures
Surgeries, radiation, biopsies, imaging, chemotherapy, etc.
Medications
Start and end dates, brand vs. generic codes, dosage, duration, and cycles
Diagnoses
Disease state, status, severity, and metastasis
full ngs panel
Complete genomic report with treatment exposure and clinical outcomes
Disease Progression
Directly-observed measures of critical endpoints
Adverse Events
Different types of adverse responses
Histology
Classification into multiple categories
Cost & Utilization
Adjudicated costs with linked claims data
Safety, Comorbidities
Pre-cancer and claims charge events
Specialty Pharmacy & Hub
Rx acquisition status details
Payer & Formulary
Drug tiers and coverage
Social Determinants
Social and physical environment factors
Cancer Subtype
Cancer type when ICD code is unknown
ECOG
Predict oft-missing performance score
Metastatic Status
Impute missing data from unstructured notes
Date of Initial Dx
Impute index event
EGFR Status
Impute specific gene mutation
Line of Therapy
Regimen or progression-based drug classes
Patient Adherence
Identify root cause of product switching
Patient Acquisition
Predict factors driving patients’ brand decision
Results
284
Eligible patients
Patients taking Line 2 treatments after Line 1:
Patients receiving DC in line 2 received Abiraterone in Line 3
Abiraterone (DA)
Results
Increased risk of death in line 2 for DA compared to DC
Patients receiving DC in line 2
received Abiraterone in Line 3
Patients receiving DA in line 2
received Cabazitaxel in Line 3
Patients taking Line 2 treatments after Line 1 Docetaxel:
out of 284
Cabazitaxel (DC)
out of 284
Abiraterone (DA)
out of 284
Other therapy (DO)